P53 and its molecular basis to chemoresistance in breast cancer

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL. 1, 2012, Pages

  Knappskog, Stian ^a,b   Lønning, Per Eystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast cancer; Chemoresistance; Chk2; P53

Indexed keywords

ANTHRACYCLINE; ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; ISOPROTEIN; MITOMYCIN C; PROTEIN MDMX; PROTEIN P53; RNA;

BREAST CANCER; DNA DAMAGE; DNA POLYMORPHISM; GENE AMPLIFICATION; GENE FUNCTION; GENE MUTATION; GENOTOXICITY; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, P53; HUMANS; MICE; MUTATION; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84857604395     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.640322     Document Type: Review

References (50)

1. Press MF, Sauter G, Buyse M, et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011;29:859-67
2. Lønning PE. Molecular basis for therapy resistance. Mol Oncol 2010;4:284-300
3. Rouse J, Jackson SP. Interfaces between the detection, signaling, and repair of DNA damage. Science 2002;297:547-51 (Pubitemid 34815330)
4. Kannan K, Amariglio N, Rechavi G, et al. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 2001;20:2225-34 (Pubitemid 32531280)
5. Yoon H, Liyanarachchi S, Wright FA, et al. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci USA 2002;99:15632-7 (Pubitemid 35403983)
6. Kato M, Paranjape T, Ullrich R, et al. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene 2009;28:2419-24
7. Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010;142:409-19
8. El-deiry WS, Tokino T, Waldman T, et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995;55:2910-19
9. Dulic V, Kaufmann WK, Wilson SJ, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76:1013-23 (Pubitemid 24106382)
10. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene 2008;27:S71-83
11. Moll UM, Wolff S, Speidel D, et al. Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol 2005;17:631-6 (Pubitemid 41540413)
12. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004;303:1010-14 (Pubitemid 38209704)
13. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-46 (Pubitemid 34606876)
14. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604 (Pubitemid 37328926)
15. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6:909-23 (Pubitemid 44862676)
16. Smeenk L, van Heeringen SJ, Koeppel M, et al. Role of p53 serine 46 in p53 target gene regulation. PLoS ONE 2011;6:e17574
17. Feng L, Hollstein M, Xu Y. Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle 2006;5:2812-19 (Pubitemid 44901744)
18. Mayo LD, Seo YR, Jackson MW, et al. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem 2005;280:25953-9 (Pubitemid 41022185)
19. Morachis JM, Murawsky CM, Emerson BM. Regulation of the p53 transcriptional response by structurally diverse core promoters. Genes Dev 2010;24:135-47
20. Ahn JY, Schwarz JK, Piwnica-Worms H, et al. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 2000;60:5934-6
21. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998;282:1893-7 (Pubitemid 28555269)
22. Berge EO, Staalesen V, Straume AH, et al. Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity. BBA Mol Cell Res 2010;1803:386-95
23. Falck J, Mailand N, Syljuasen RG, et al. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001;410:842-7 (Pubitemid 32303786)
24. Chrisanthar R, Knappskog S, Løkkevik E, et al. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 2008;3:e3062; 1-15
25. Geisler S, Lønning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-12 (Pubitemid 32685830)
26. Geisler S, Børresen-Dale AL, Johnsen H, et al. TP53 gene mutations predict the response to neoadjuvant treatment with FUMI in locally advanced breast cancer. Clin Cancer Res 2003;9:5582-8 (Pubitemid 37499478)
27. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50-6 (Pubitemid 30064975)
28. Preudhomme C, Fenaux P. The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies. Br J Haematol 1997;98:502-11 (Pubitemid 27386527)
29. Lønning PE. Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance. Trends Mol Med 2004;10:113-18 (Pubitemid 38293346)
30. Chrisanthar R, Knappskog S, Løkkevik E, et al. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS ONE 2011;6(4):e19249; s1-10
31. Bonnefoi H, Piccart M, Bogaerts J, et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011;12:527-39
32. Olivier M, Langerod A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006;12:1157-67 (Pubitemid 43342504)
33. Bourdon JC, Khoury MP, Diot A, et al. p53 mutant breast cancer patients expressing p53gamma have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res 2011;13(1):R7
34. Bertheau P, Turpin E, Rickman DS, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicincyclophosphamide regimen. PLoS Med 2007;4:e90; 585-594
35. Bourdon JC, Fernandes K, Murray-Zmijewski F, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005;19:2122-37 (Pubitemid 41330315)
36. Agirre X, Vizmanos JL, Calasanz MJ, et al. Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients. Oncogene 2003;22:1070-2 (Pubitemid 36313150)
37. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006;38:873-5 (Pubitemid 44141653)
38. Jiang H, Reinhardt HC, Bartkova J, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009;23:1895-909
39. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001;15:2177-96 (Pubitemid 32843830)
40. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 2001;11:71-7 (Pubitemid 32119281)
41. Boehme KA, Blattner C. Regulation of p53-insights into a complex process. Crit Rev Biochem Mol Biol 2009;44:367-92
42. Maya R, Balass M, Kim ST, et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev 2001;15:1067-77 (Pubitemid 32417300)
43. Cheng Q, Chen LH, Li ZY, et al. ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J 2009;28:3857-67
44. Pizarro JG, Folch J, de la Torre AV. ATM Is involved in cell-cycle control through the regulation of retinoblastoma protein phosphorylation. J Cell Biochem 2010;110:210-18
45. Sirvent N, Coindre JM, Maire G, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 2007;31:1476-89 (Pubitemid 47482460)
46. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602 (Pubitemid 39535748)
47. Bond GL, Hu WW, Levine A. A single nucleotide polymorphism in the MDM2 gene: From a molecular and cellular explanation to clinical effect. Cancer Res 2005;65:5481-4 (Pubitemid 40911143)
48. Knappskog S, Bjornslett M, Myklebust LM, et al. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in caucasians. Cancer Cell 2011;19:273-82
49. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010;20:299-309
50. Berge EO, Knappskog S, Geisler S, et al. Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers. Mol Cancer 2010;9:173